Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/emeCCfbwocfDlhaVLwLY

March 4, 2013
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • Former FDA chief: Reform rules for clinical trials
    Changing the FDA's burdensome requirements for clinical trials could help double the number of new drug approvals, former FDA Commissioner Andrew von Eschenbach and University of Chicago public policy professor Tomas Philipson write. Phase III studies are unnecessarily large and cumbersome for more precise and personalized medicine. Adopting smaller, quicker adaptive studies with post-market oversight would mean greater innovation and a better economy. Bloomberg (2/28) LinkedInFacebookTwitterEmail this Story
 
Reach Biopharmaceutical Decision-Makers with SmartBrief
You read SmartBrief, but did you know that SmartBrief publishes more than 30 unique e-newsletters for life science and health care professionals? SmartBrief delivers an engaged audience of more than a half-million business leaders, driving best-in-class click through rates and consistent reader engagement. Find out if we're reaching your target audience or contact us.
  Health Care & Policy 
  • Novartis' Ilaris wins EU approval for acute gouty arthritis
    Novartis obtained approval from the European Commission to market Ilaris in adult patients with acute gouty arthritis who can't tolerate current treatment options. Ilaris, an interleukin-1 beta inhibitor, is already cleared for cryopyrin-associated periodic syndromes. Reuters (3/1), RTT News (3/1) LinkedInFacebookTwitterEmail this Story
  • Takeda allies with Resolve to develop autoimmune disease drugs
    Takeda Pharmaceutical and Resolve Therapeutics agreed to collaborate on treatments for systemic lupus erythematosus and other autoimmune disorders, with an initial focus on Resolve's nuclease Fc fusion protein RSLV-132. The deal gives Takeda an exclusive option to license all Resolve compounds following a study on RSLV-132. Resolve will get $8 million for clinical development, a potential option exercise payment and as much as $247 million in milestone fees plus sales royalties. Genetic Engineering & Biotechnology News (2/28) LinkedInFacebookTwitterEmail this Story
  • Celgene's psoriasis drug apremilast performs well in trial
    More psoriasis patients who took Celgene's experimental drug apremilast experienced improvements in symptoms compared with patients who took a placebo, a late-stage trial found. Celgene plans to submit the drug for FDA approval this year. Reuters (3/2) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Food & Agriculture 
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • Sundrop finalizes purchase of land in La. for fuel project
    Colorado-based Sundrop Fuels has completed the approximately $4.7 million purchase of more than 1,213 acres in Louisiana for a pilot-scale plant for producing "green gasoline." The proposed $500 million facility will use biomass and natural gas to produce the drop-in fuel. Sundrop also bought an adjacent property that it plans to refurbish to serve as its state headquarters, as well as house its maintenance and fabrication operations. The Town Talk (Alexandria, La.) (3/1) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
The man who insists upon seeing with perfect clearness before he decides, never decides. Accept life, and you must accept regret."
--Henri Frédéric Amiel,
Swiss philosopher, poet and critic


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information